Drugs / CALAA-01
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00689065 | May 2008 → Sep 2012 | cancer | Calando Pharmaceuticals | Terminated | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2012-08-30 | Arrowhead Pharmaceuticals | Arrowhead Completes Enrollment in Phase 1b Trial of RNAi Drug Candidate CALAA-01 arrowheadpharma.com ↗ |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CALAA-01 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00689065 ↗ |
| Action | Inhibit | “This siRNA inhibits tumor growth via RNA interference to reduce expression of the M2 subunit of ribonucleotide reductase (R2).” NCT00689065 ↗ |
| Route | Intravenous | “administered intravenously” NCT00689065 ↗ |